A comprehensive view of regeneron pharmaceuticals inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Regeneron reports Q1 net profit down 13% from a year ago at US$974.0M, with revenue up 17% at US$3.0B; growth driven by increased sales of eye medicine Eylea aflibercept, revenue from partners, tempered by US$58.0M write-off of REGEN-COV COVID-19 therapy

Regeneron acquires Checkmate Pharmaceuticals and its investigational drug vidutolimod, a possible best-in-class TLR9 agonist to treat melanoma, skin, head, neck cancers; US$250M deal to close mid-year, will strengthen Regeneron's immuno-oncology portfolio

FDA extends review of BLA for REGEN-COV casirivimab, imdevimab COVID-19 treatment to review trial data studying drug’s use as pre-exposure prophylactic; REGEN-COV has treated millions of COVID-19 patients in US, worldwide

Biotech Pulse: Regeneron acquires cancer drug firm Checkmate Parmaceuticals for US$250M; Moderna reports bivent COVID-19 booster superior against Beta, Omicron variants after six months and FDA gives AstraZeneca Enhertu lung cancer drug priority review

FDA accepts priority review of Regeneron, Sanofi’s sBLA for injectable Dupixent dupilumab 300 mg weekly to treat eosinophilic esophagitis in adult, pediatric patients aged 12 years and older; 160,000 patients in US are currently treated for EoE

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count